UroGen Pharma: Peers

The FY2025 (Dec) proxy of UroGen Pharma names 18 peer companies for pay. Among UroGen Pharma and these peers, CEO pay was 6th highest of 7 and total shareholder return was the highest of 6.

6th highest of 7in UroGen Pharma and its pay peers, FY2025 (Dec) by CEO pay:

$2.8M$9.7M

1st highest of 6in UroGen Pharma and its pay peers, FY2025 (Dec) by total shareholder return:

$14$264

Pay peer group, FY2025 (Dec) proxy

Arcus Biosciences
IDEAYA Biosciences
Arvinas
Kura Oncology
Rigel Pharmaceuticals
Tango TherapeuticsNot disclosed
Acrivon TherapeuticsNot disclosedNot disclosed
Aura BiosciencesNot disclosedNot disclosed
C4 TherapeuticsNot disclosedNot disclosed
Day One BiopharmaceuticalsNot disclosedNot disclosed
ErascaNot disclosedNot disclosed
Olema PharmaceuticalsNot disclosedNot disclosed
Sutro BiopharmaNot disclosedNot disclosed
Syndax PharmaceuticalsNot disclosedNot disclosed
Tyra BiosciencesNot disclosedNot disclosed
XencorNot disclosedNot disclosed
Y-mAbs TherapeuticsNot disclosedNot disclosed
iTeos TherapeuticsNot disclosedNot disclosed
18 companies

Changes by year

No proxy on file names a change to the peer group.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.